Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The GRK2–delta-opioid receptor protein-protein interface is the molecular region where G protein-coupled receptor kinase 2 (GRK2) interacts physically with the delta-opioid receptor (DOR, a GPCR). GRK2 is a serine/threonine kinase involved in the phosphorylation and desensitization of activated GPCRs, including opioid receptors. Upon interaction, GRK2 phosphorylates the activated DOR, initiating receptor desensitization and internalization, which modulates opioid signaling and analgesic response. The precise structure and role of the interface are subjects of research as part of efforts to understand and manipulate opioid signal regulation, pain control, and related disease pathways. Currently, the interface itself is a subject of mechanistic study rather than a direct drug target.
GRK2 inhibitors block the phosphorylation/desensitization of GPCRs, potentially enhancing receptor sensitivity. DOR agonists or antagonists modulate opioid receptor activity. Inhibition of protein–protein interaction could theoretically modulate opioid signaling, but no approved drugs do so.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on G protein-coupled receptor kinase 2 – delta-opioid receptor protein-protein interface (GRK2-DOR interface).